A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events a Comparison of Glyburide with Other Secretagogues and with Insulin

Total Page:16

File Type:pdf, Size:1020Kb

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events a Comparison of Glyburide with Other Secretagogues and with Insulin Reviews/Commentaries/ADA Statements META-ANALYSIS A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events A comparison of glyburide with other secretagogues and with insulin 1,2 2 AZIM S. GANGJI, MD, FRCPC CHARLES H. GOLDSMITH, PHD 1–2% (6). Differences in chemical struc- 2,3 1,2 TALI CUKIERMAN, MD CATHERINE M. CLASE, MB, FRCPC ture, pharmacokinetic, and pharmacody- 2,3 HERTZEL C. GERSTEIN, MD, FRCPC namic properties between sulfonylureas may lead to differences in the rates of hy- poglycemic reactions. Glyburide (called OBJECTIVE — Glyburide is the most widely used sulfonylurea but has unique pharmaco- glibenclamide in Europe), the most dynamic properties that may increase harm. We hypothesized that glyburide causes more hy- widely used sulfonylurea (7), has a rela- poglycemia and cardiovascular events than other secretagogues or insulin. tively long terminal half-life in chronic dosing compared with other sulfonyl- RESEARCH DESIGN AND METHODS — Data sources were Medline, Embase, ureas, owing to its high affinity for the Cochrane, and three other web-based clinical trial registers (1966–2005). Parallel, randomized, ␤ controlled trials in people with type 2 diabetes comparing glyburide monotherapy with mono- -cell sulfonylurea receptor and the accu- therapy using secretagogues or insulin were selected. Outcomes were hypoglycemia, glycemic mulation of active metabolites that are ex- control, cardiovascular events, body weight, and death. Titles and abstracts of 1,806 publications creted through the kidney (7). Several were reviewed in duplicate and 21 relevant articles identified. Data on patient characteristics, observational studies have reported in- interventions, outcomes, and validity were extracted in duplicate using predefined criteria. creased rates of hypoglycemia with the use of glyburide compared with other sul- RESULTS — Glyburide was associated with a 52% greater risk of experiencing at least one fonylureas (3,4). A systematic review of episode of hypoglycemia compared with other secretagogues (relative risk 1.52 [95% CI 1.21– randomized controlled trials (RCTs) evalu- 1.92]) and with 83% greater risk compared with other sulfonylureas (1.83 [1.35–2.49]). Gly- buride was not associated with an increased risk of cardiovascular events (0.84 [0.56–1.26]), ating the risk for hypoglycemia associated death (0.87 [0.70–1.07]), or end-of-trial weight (weighted mean difference 1.69 kg [95% CI with the use of glyburide has not, to our Ϫ0.41 to 3.80]) compared with other secretagogues. Limitations included suboptimal reporting knowledge, been previously conducted. of original trials. Loss to follow-up exceeded 20% in some studies, and major hypoglycemia was The University Group Diabetes Pro- infrequently reported. gram (UGDP) RCT (8) noted excess car- diac deaths in patients treated with CONCLUSIONS — Glyburide caused more hypoglycemia than other secretagogues and tolbutamide; whether this was attribut- other sulfonylureas. Glyburide was not associated with an increased risk of cardiovascular able to higher baseline cardiac risk in the events, death, or weight gain. patients allocated to tolbutamide or to a Diabetes Care 30:389–394, 2007 true biological effect has been widely de- bated. Consistent with the findings of the UGDP study, experimental laboratory he global prevalence of diagnosed risk for severe hypoglycemia, which is as- data have suggested that sulfonylureas, type 1 and 2 diabetes was estimated sociated with mortality and morbidity particularly glyburide, might increase the to be 2.8% in 2000 and projected to (3,4). T risk of cardiovascular events. During cor- be 4.4% by 2030 (1). The UK Prospective Sulfonylurea drugs bind the sulfonyl- ϩ onary angioplasty, with each subsequent Diabetes Study (UKPDS) showed that im- urea receptor, an ATP-sensitive K chan- balloon dilatation, the extent of ST seg- proving glycemic control reduced long- nel, and inhibit potassium efflux, which ment depression decreases and the time term microvascular complications (2). facilitates insulin secretion (5). Compared However, intensive therapy increases the with placebo, they reduce A1C levels by to onset of ST depression and the time to onset of angina increase. This phenome- ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● non, known as ischemic preconditioning, From the 1Division of Nephrology, McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, is thought also to occur in acute coronary Canada; the 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, On- syndromes. Sulfonylurea-induced potas- tario, Canada; and the 3Division of Endocrinology & Metabolism and Population Health Research Institute, sium efflux has been shown to reduce McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. cardiac ischemic preconditioning in ani- Address correspondence and reprint requests to Catherine M. Clase, 708-25 Charlton Ave. East, Hamil- ton, Ontario L8P 3P7, Canada. E-mail: [email protected]. mal studies (9). In humans undergoing Received for publication 23 August 2006 and accepted in revised form 12 November 2006. coronary angioplasty, the infusion of gli- Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/ mepiride has the same effect on ST de- dc06-1789. pression and time to onset of angina as Abbreviations: FPG, fasting plasma glucose; RCT, randomized controlled trial; UKPDS, UK Prospective Diabetes Study; WMD, weighted mean difference. placebo, whereas the infusion of gly- A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion buride leads to a reduction in each of the factors for many substances. effects of preconditioning (10). DOI: 10.2337/dc06-1789 This systematic overview of random- © 2007 by the American Diabetes Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby ized controlled trials in people with type 2 marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. diabetes was conducted to determine DIABETES CARE, VOLUME 30, NUMBER 2, FEBRUARY 2007 389 Hypoglycemia: glyburide vs. secretagogues/insulin tent of agreement between reviewers. Dis- agreements were resolved by consensus. Validity assessment We assessed validity in duplicate using the following criteria: 1) method of ran- domization, 2) presence of allocation con- cealment, 3) blinding, 4) loss to follow- up, and 5) reporting of an intention-to- treat analysis. Data abstraction For each study, we abstracted, in dupli- cate: 1) inclusion and exclusion criteria; 2) baseline characteristics for the different treatment arms, including the number of participants at the start of the study; 3) the intervention and comparator (including dose, frequency, target A1C, and A1C achieved); 4) follow-up period and num- ber of participants at study completion; and 5) the definitions used to report hy- poglycemia and cardiovascular events. For each treatment arm we abstracted: 1) Figure 1—Study flow diagram. AG, Azim S. Gangji; TC, Tali Cukierman. all episodes of hypoglycemia (number of participants with one or more episodes and number of episodes per unit of per- whether people taking glyburide are at in- tially appropriate articles and each was re- son-time), 2) number of episodes of major creased risk for hypoglycemia or cardio- viewed independently for eligibility. and minor hypoglycemia, 3) number of vascular events compared with those cardiovascular events, 4) number of taking other secretagogues (other sulfo- Study selection deaths from any cause, and 5) weight nylureas and meglitinides) or those taking Eligible studies 1) described people with change and end-of-trial weight. When the insulin. For completeness of our analysis type 2 diabetes; 2) compared glyburide study included more than two arms, we of important harms, we also examined monotherapy with monotherapy using chose the comparator with the largest weight gain. other sulfonylureas, meglitinides, or insu- number of people. lin; 3) reported one or more of the follow- RESEARCH DESIGN AND ing outcomes: hypoglycemia (major, Data analysis METHODS — We followed the rec- minor, or all), cardiovascular events, or We summarized studies that compared ommendations of the Quality of Report- weight change; 4) described a parallel de- glyburide with other secretagogues sepa- ing of Meta-Analyses (QUOROM) sign RCT; and 5) were written in English. rately from studies that compared gly- conference (online appendix 1 [available For hypoglycemia and cardiovascular buride with insulin. Because of the at http://dx.doi.org/10.2337/dc06-1789]) events, we accepted the definition or out- unique pharmacokinetic and pharmaco- (11). come cluster reported in the original dynamic properties of glyburide, we pre- manuscript. Cardiovascular events in- specified a subgroup analysis comparing Search strategy cluded incident myocardial infarction, glyburide with other sulfonylureas. We searched biomedical databases (Med- stroke, amputation, episodes of conges- We assessed patient characteristics, line, Embase, the Cochrane library, clini- tive heart failure, or cardiovascular death. interventions, and outcomes for clinical caltrials.gov, controlled-trials.com, and Where multiple outcomes were reported, heterogeneity and used the I2 statistic to the U.K. national register of RCTs) and we selected the cluster that most closely quantify the
Recommended publications
  • Enhancement of Dissolution and Oral Bioavailability of Gliquidone with Hydroxy Propyl-Β-Cyclodextrin
    ORIGINAL ARTICLES Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-b-cyclodextrin S. Sridevi, A. S. Chauhan, K. B. Chalasani, A. K. Jain, P. V. Diwan Received November 15, 2002, accepted May 5, 2003 Dr. Prakash V. Diwan, Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad – 500 007 A.P., India [email protected] Pharmazie 58: 807–810 (2003) The virtual insolubility of gliquidone in water results in poor wettability and dissolution characteristics, which may lead to a variation in bioavailability. To improve these characteristics of gliquidone, binary systems with hydroxypropyl-b-cyclodextrin (HP-b-CD) were prepared by classical methods such as physical mixing, kneading, co-evaporation and co-lyophilization. The solid state interaction between the drug and HP-b-CD was assessed by evaluating the binary systems with X-ray diffraction, differen- tial scanning calorimetry and IR- spectroscopy. The results establish the molecular encapsulation and amorphization of gliquidone. The phase solubility profile of gliquidone in aqueous HP-b-CD vehicle À1 resulted in an AL type curve with a stability constant of 1625 M . The dissolution rate of binary sys- tems was greater than that of pure drug and was significantly higher in the case of co-lyophilized and co-evaporated systems. Upon oral administration, [AUC]0-a was significantly higher in case of co-lyo- philized (2 times) and co-evaporated systems (1.5 times) compared to pure drug suspension while other binary systems showed only a marginal improvement. The study ascertained the utility of HP-b- CD in enhancing the oral bioavailability of gliquidone, and points towards a strong influence of the preparation method on the physicochemical properties.
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • PRANDIN® (Repaglinide) Tablets (0.5, 1, and 2 Mg) Rx Only
    PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only DESCRIPTION PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)- butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues. The structural formula is as shown below: CH3 O OH H3C O N O H N CH3 Repaglinide is a white to off-white powder with molecular formula C27 H36 N2 O4 and a molecular weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, maize starch, polacrilin potassium, povidone, glycerol (85%), magnesium stearate, meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron oxides (yellow and red, respectively) as coloring agents. CLINICAL PHARMACOLOGY Mechanism of Action Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
    [Show full text]
  • MRI Evidence That Glibenclamide Reduces Acute Lesion Expansion in a Rat Model of Spinal Cord Injury
    Spinal Cord (2013) 51, 823–827 OPEN & 2013 International Spinal Cord Society All rights reserved 1362-4393/13 www.nature.com/sc ORIGINAL ARTICLE MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury JM Simard1,2,3, PG Popovich4, O Tsymbalyuk1, J Caridi1, RP Gullapalli5, MJ Kilbourne6 and V Gerzanich1 Study design: Experimental, controlled, animal study. Objectives: To use non-invasive magnetic resonance imaging (MRI) to corroborate invasive studies showing progressive expansion of a hemorrhagic lesion during the early hours after spinal cord trauma and to assess the effect of glibenclamide, which blocks Sur1-Trpm4 channels implicated in post-traumatic capillary fragmentation, on lesion expansion. Setting: Baltimore. Methods: Adult female Long–Evans rats underwent unilateral impact trauma to the spinal cord at C7, which produced ipsilateral but not contralateral primary hemorrhage. In series 1 (six control rats and six administered glibenclamide), hemorrhagic lesion expansion was characterized using MRI at 1 and 24 h after trauma. In series 2, hemorrhagic lesion size was characterized on coronal tissue sections at 15 min (eight rats) and at 24 h after trauma (eight control rats and eight administered glibenclamide). Results: MRI (T2 hypodensity) showed that lesions expanded 2.3±0.33-fold (Po0.001) during the first 24 h in control rats, but only 1.2±0.07-fold (P40.05) in glibenclamide-treated rats. Measuring the areas of hemorrhagic contusion on tissue sections at the epicenter showed that lesions expanded 2.2±0.12-fold (Po0.001) during the first 24 h in control rats, but only 1.1±0.05-fold (P40.05) in glibenclamide-treated rats.
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • International Journal of Pharmacy Teaching & Practices (IJPTP)
    Vol 5, Issue 3 Supplement 2014 International Journal of Pharmacy Teaching & Practices (IJPTP) Clinical Case Reports - September, 2014 Published by: DRUNPP Association of Sarajevo, Bosnia & Herzegovinia www.iomcworld.com/ijptp email: [email protected] ISSN: 1986-8111 International Journal of Pharmacy Teaching & Practices, Vol5, issue3, Supplement I, 1020-1552. EDITORIAL BOARD Editor-in-Chief Dr. Syed Wasif Gillani Associate Prof. Dr. Azmi Sarriff Editorial Assistant Dr. Mostafa Nejati Executive Editors Prof. Dr. Syed Azhar Syed Sulaiman Dr. Waffa Mohamed El-Anor Ahmed Rashed Prof. Dr. Mark Raymond Mr. Robert Hougland Advisory Board Members Dr. Mensurak Kudumovic Dr. Jasmin Musanovic Dr. Monica Gaidhane Assoc.Prof. Dr. Mok.T Chong Dr. Syed Tajuddin Syed Hassan Dr. Sumeet Dwivedi Dr. Dibyajyoti saha EDITORIAL ADDRESS: KA311, KEYANGANG, BANDAR SUNWAY, SELANGOR, MALAYSIA PUBLISHED BY: DRUNPP, SARAJEVO, BOLNICKA BB. VOLUME 5, ISSUE 3, SUPP I, 2014 ISSN: 1986-8111, INDEXED ON: EBSCO PUBLISHING (EP)USA, INDEX COPERNICUS (IC) POLAND 1020 International Journal of Pharmacy Teaching & Practices, Vol5, issue3, Supplement I, 1020-1552. Table of Contents 1. ISCHIALGIA AND LUNG TUMOR IN MINTOHARDJO HOSPITAL ............................................................ 1026 2. THE MONITORING OF DRUG THERAPY FOR CRF (Chronic Renal Failure) PATIENT IN Dr. MINTOHARDJO, INDONESIAN NAVY MILITARY HOSPITAL.............................................................................................. 1031 3. DIABETES MELLITUS TYPE II, and CHRONIC RENAL FAILURE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Package Leaflet: Information for the User
    Package leaflet: Information for the patient [Repaglinide] 0.5 mg tablets [Repaglinide] 1.0 mg tablets [Repaglinide] 2.0 mg tablets repaglinide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What [Repaglinide] is and what it is used for 2. What you need to know before you take [Repaglinide] 3. How to take [Repaglinide] 4. Possible side effects 5. How to store [Repaglinide] 6. Contents of the pack and other information 1. What [Repaglinide] is and what it is used for [Repaglinide] is an oral antidiabetic agent containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces (formerly known as non-insulin-dependent diabetes mellitus or maturity onset diabetes). [Repaglinide] is used to control type 2 diabetes as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Effects of Glibenclamide and Glimepiride Compared in Type II DM Patients in Accordance with Lipid Parameters, ESF and Glycated Haemoglobin
    British Journal of Applied Science & Technology 10(3): 1-10, 2015, Article no.BJAST.17537 ISSN: 2231-0843 SCIENCEDOMAIN international www.sciencedomain.org Effects of Glibenclamide and Glimepiride Compared in Type II DM Patients in Accordance with Lipid Parameters, ESF and Glycated Haemoglobin K. Chandra Mouli Krishna1, B. Sowmya2, Bandopadhyay Mamata3 and M. Prasad Naidu4* 1NRI Institute of Medical College, Sangivalasa, Visakhapatnam -531162, Andhra Pradesh, India. 2Kamala Nursing Home, Marripalem, Visakhapatnam - 530018, Andhra Pradesh, India. 3Department of Pharmacology, Maharaja Institute of Medical Sciences, Nellimarla, Vizinagaram - 535217, Andhra Pradesh, India. 4Department of Biochemistry, Narayana Medical College and Hospital, Nellore-524003, Andhra Pradesh, India. Authors’ contributions This work was carried out in collaboration between all authors. All authors read and approved the final manuscript. Article Information DOI: 10.9734/BJAST/2015/17537 Editor(s): (1) Gautam R. Ullal, Course Director Neuroscience and Foundations of Clinical Medicine, Medical University of Americas, West Indies. Reviewers: (1) Ayşenur Yeğin, Clinical Biochemistry, Antalya Research and Educational Hospital, Turkey. (2) Anonymous, The Third Hospital of Hebei Medical University, China. (3) Anonymous, MGM Medical College, Navi-Mumbai, India. Complete Peer review History: http://sciencedomain.org/review-history/9912 Received 17th March 2015 th Original Research Article Accepted 5 June 2015 Published 27th June 2015 ABSTRACT The population of Indian adults suffering from diabetes is expected to increase threefold, from 19.4 million in 1995 to 57.2 million in 2025. The objective of the study was to evaluate the efficacy and safety of antidiabetic drug and to find out their cardio protective action in patients with diabetes mellitus.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • 9567-Sandoz Repaglinide Product Monograph.Pdf
    PRODUCT MONOGRAPH PrSANDOZ REPAGLINIDE (Repaglinide) 0.5 mg, 1 mg and 2 mg tablets Oral Antidiabetic Agent Manufacturer's Standard Sandoz Canada Inc. Date of Revision: 110 de Lauzon August 16, 2018 Boucherville, QC J4B 1E6 Submission Control No: 218326 Sandoz Repaglinide Page 1 of 43 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 11 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ............................................................................................................... 17 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 18 STORAGE AND STABILITY ......................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]